GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Check Cap Ltd.
Check-Cap is an Israeli company developing a unique swallowable capsule for colon cancer screening. Its stock price reflects the long and arduous battle to gain FDA approval for its innovative but complex technology.
Share prices of companies in the market segment - Cancer analysis
Check-Cap is an Israeli medical company that has developed the innovative C-Scan capsule for colorectal cancer screening without bowel preparation. We've categorized it under "Cancer Analysis." The chart below shows how the market is evaluating new technologies in cancer diagnostics.
Broad Market Index - GURU.Markets
Check-Cap is an Israeli company that has developed an innovative swallowable capsule for colorectal cancer screening without bowel preparation. As a pioneer, it is included in our GURU.Markets index. The chart below shows the overall market trend. Compare it with Check-Cap's performance.
Change in the price of a company, segment, and market as a whole per day
CHEK - Daily change in the company's share price Check Cap Ltd.
The daily price change of Check-Cap Ltd., a developer of a cancer screening capsule, reflects volatility in the medical device sector. The indicator demonstrates sensitivity to news about clinical trials and regulatory approvals.
Daily change in the price of a set of shares in a market segment - Cancer analysis
Check-Cap Ltd. is a company in the medical device sector. This chart illustrates the high volatility of the MedTech industry. Comparing this to CHEK, with its innovative screening capsule, helps assess the riskiness of its business.
Daily change in the price of a broad market stock, index - GURU.Markets
Check-Cap is an Israeli company that has developed a swallowable capsule for colon cancer screening. The shares of this innovative medtech company are reacting to clinical successes and regulatory decisions, contributing to the overall volatility of the healthcare sector.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Check Cap Ltd.
Check-Cap Ltd.'s year-to-date performance reflects the long-term development of its C-Scan capsule for colorectal cancer screening. Its 12-month market cap depends entirely on progress toward FDA approval. Success could offer patients a less invasive and painless alternative to traditional colonoscopy.
Annual dynamics of market capitalization of the market segment - Cancer analysis
Check-Cap Ltd. is an Israeli medical device company that has developed a unique, ingestible capsule for colorectal cancer screening. Its stock price is entirely speculative and based on investors' belief in its ability to commercialize its breakthrough technology, not on current financial results.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Check-Cap, with its innovative cancer screening capsule, is a story about how one technology can transform medicine. Its dynamics, compared to the market, reflect the anticipation of a verdict from regulators and the medical community. Success will mean a revolution in diagnostics and a stock surge; failure will mean oblivion.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Check Cap Ltd.
Check-Cap is developing a swallowable capsule for cancer screening. While it's in the development stage, its monthly pricing is dependent on news. Progress in clinical trials and interactions with the FDA are key events shaping investor expectations.
Monthly dynamics of market capitalization of the market segment - Cancer analysis
Check-Cap is an Israeli company developing the innovative C-Scan capsule for colorectal cancer screening. The patient swallows the capsule, which scans the colon without the need for invasive preparation. The graph below shows the dynamics of the medical equipment sector, where non-invasive diagnostics is a major trend.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Check-Cap is developing an innovative capsule for colon cancer screening. It's a medical startup whose value is based on the potential of its technology. Its shares are driven by news of clinical trials and regulatory approvals, completely ignoring overall market trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Check Cap Ltd.
Check-Cap is developing an innovative capsule for colon cancer screening. Its weekly stock price reflects its long journey to FDA approval. Any news from the regulator triggers extreme price movements.
Weekly dynamics of market capitalization of the market segment - Cancer analysis
Check-Cap is developing an innovative cancer screening capsule. The chart compares the weekly stock price of this medtech company with its sector. Are the sharp price movements a reaction to news about clinical trials and product approval, or is this a general trend in diagnostics?
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
As a medical technology company, Check-Cap Ltd. should be less dependent on economic cycles. The chart will show how insulated the company's shares are from general market fluctuations, moving with product news and regulatory decisions while ignoring macroeconomic noise.
Market capitalization of the company, segment and market as a whole
CHEK - Market capitalization of the company Check Cap Ltd.
The chart for Check-Cap Ltd. shows the long and arduous history of developing a noninvasive cancer screening test. The market capitalization of the company, which creates a swallowable capsule for polyp detection, reflects all the ups and downs of clinical trials and the search for regulatory approval.
CHEK - Share of the company's market capitalization Check Cap Ltd. within the market segment - Cancer analysis
Check-Cap has developed a unique capsule for colorectal cancer screening that patients simply swallow. Its market capitalization in the oncology diagnostics segment reflects the revolutionary potential of this non-invasive technology. The company's market share reflects its bet that its product will replace or complement traditional colonoscopy, making screening more accessible.
Market capitalization of the market segment - Cancer analysis
Check-Cap is developing a swallowable capsule for colon cancer screening. What is the scale of this innovation? The graph below shows the overall market capitalization of the cancer screening sector. Its growth reflects the enormous need for non-invasive and convenient methods for early cancer diagnosis.
Market capitalization of all companies included in a broad market index - GURU.Markets
The Check-Cap graph shows the development history of an innovative but complex colon cancer screening technology. The market capitalization of the company that created the swallowable scanning capsule reflects all the challenges on the road to approval and commercialization. It's a chart full of hope and regulatory hurdles.
Book value capitalization of the company, segment and market as a whole
CHEK - Book value capitalization of the company Check Cap Ltd.
For Check-Cap, which is developing a colon cancer screening capsule, book value is its tangible assets: capsule assembly lines, R&D centers, and financial reserves. The chart below shows how the company invested in creating this innovative diagnostic foundation.
CHEK - Share of the company's book capitalization Check Cap Ltd. within the market segment - Cancer analysis
Check-Cap Ltd. is developing a unique cancer screening capsule. Its tangible assets include R&D centers and production lines for assembling these complex miniature devices. The chart shows the company's control over this advanced medical diagnostics manufacturing infrastructure.
Market segment balance sheet capitalization - Cancer analysis
Check-Cap is developing a cancer screening capsule. The medical equipment sector, as the chart shows, is capital-intensive. Check-Cap is an innovator. Its capital is invested in R&D and production of a unique device that could change the approach to diagnostics.
Book value of all companies included in the broad market index - GURU.Markets
Check-Cap's assets are not drugs, but rather manufacturing facilities for the unique C-Scan capsule, designed for non-invasive colorectal cancer screening. The book value reflects the investment in this breakthrough, yet complex, diagnostic technology.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Check Cap Ltd.
Check-Cap is developing a swallowable capsule for colorectal cancer screening. The company has no commercial product. Its market capitalization is a bet on its C-Scan technology. The chart shows the risks and hopes associated with the development of this non-invasive diagnostic device.
Market to book capitalization ratio in a market segment - Cancer analysis
Check-Cap is developing an innovative capsule for colon cancer screening without the need for invasive procedures. The company's value is determined by the potential of this technology. The chart shows how the market assesses its chances of commercializing this breakthrough product.
Market to book capitalization ratio for the market as a whole
Check-Cap is developing a cancer screening capsule. The company's entire value lies in this technology and its patents. This chart clearly demonstrates the extreme gap between its book value (R&D costs) and its market value, based on investors' hopes for a revolution in medical diagnostics.
Debts of the company, segment and market as a whole
CHEK - Company debts Check Cap Ltd.
Check-Cap is developing an innovative colon cancer screening capsule, an alternative to colonoscopy. The development and clinical trials of such a complex medical device require significant investment over many years. This chart shows how the company is raising capital to finance its long-term efforts to bring this technology to market.
Market segment debts - Cancer analysis
Check-Cap is developing an innovative capsule for colorectal cancer screening. As a medical technology company in the development and clinical trials phase, it has no sales revenue. This chart reflects its financial position and its complete reliance on capital raising to bring its product to market.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Check Cap Ltd.
Check-Cap is developing an innovative capsule for colon cancer screening. This chart shows the financial structure of the medical technology company. Until the product is commercialized and revenue is stable, debt is a significant risk. It could drain the company's resources before its technology gains market acceptance.
Market segment debt to market segment book capitalization - Cancer analysis
Check-Cap is developing an innovative capsule for colorectal cancer screening, a less invasive alternative to colonoscopy. This market is huge. The chart shows the overall debt burden in the medical device sector, which helps assess how the company finances its lengthy and expensive clinical trials and approval process.
Debt to book value of all companies in the market
Check-Cap Ltd. is an Israeli company developing an innovative capsule for colon cancer screening. After years of development, it is at a critical stage of obtaining approvals. This graph shows that debt financing is unavailable to the company in this situation, and its future depends on the success of the technology and investor support.
P/E of the company, segment and market as a whole
P/E - Check Cap Ltd.
This chart shows the valuation of Check-Cap, a company developing a colon cancer screening capsule. P/E ratios are not applicable here. The company's valuation is a bet that its less invasive diagnostic method will gain approval and become a popular alternative to traditional colonoscopy.
P/E of the market segment - Cancer analysis
Check-Cap is developing the innovative C-Scan capsule, designed for colorectal cancer screening without the need for bowel preparation. It offers a potentially more convenient alternative to colonoscopy. This chart shows the average market value for this disruptive, yet still-developing, technology.
P/E of the market as a whole
Check-Cap is developing an innovative, swallowable capsule for colorectal cancer screening. Its pricing is a pure bet on the success of this technology as a less invasive alternative to colonoscopy. It is unrelated to the general economic cycles reflected here and depends entirely on the results of clinical trials and regulatory approval.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Check Cap Ltd.
Check-Cap is developing an innovative, swallowable capsule for colorectal cancer screening, offering a less invasive alternative to colonoscopy. This timeline reflects investor expectations for clinical trials and FDA approval. The company's valuation is entirely dependent on the future success of this breakthrough technology.
%20P%2FE%20Check%20Cap%20Ltd.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Check-Cap-Ltd.&v=1772554272412 "Chart of the company's future (projected) P/E Check Cap Ltd.")
Future (projected) P/E of the market segment - Cancer analysis
Check-Cap is developing an innovative, swallowable capsule for colorectal cancer screening. Its valuation, relative to other companies in the medical diagnostics field, reflects the expectations and risks associated with its unique technology. Investors are betting that its non-invasive method will become an alternative to traditional colonoscopy.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20analysis&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-analysis&v=1772554272435 "Future (projected) P/E graph of the market segment - Cancer analysis")
Future (projected) P/E of the market as a whole
Check-Cap is developing an innovative capsule for colorectal cancer screening that requires no bowel preparation. The company's success depends on regulatory approval and technology adoption. This chart reflects the overall risk appetite of investors. For companies with breakthrough medical devices, a positive environment is essential for raising capital for commercialization.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772554272469 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Check Cap Ltd.
Check-Cap is developing an innovative, swallowable capsule for colorectal cancer screening. The financial performance shown here reflects the costs of research and clinical trials for this breakthrough product. The company's future depends on regulatory approval, primarily from the FDA.
Profit of companies in the market segment - Cancer analysis
Check-Cap is developing an innovative, ingestible capsule for colorectal cancer screening. This graph shows the overall profitability of the oncology diagnostics sector. It helps understand the market and healthcare systems' readiness to embrace breakthrough, but potentially expensive, early detection technologies.
Overall market profit
Check-Cap is developing an innovative capsule for colorectal cancer screening. This medical device is still in the development stage. Its future depends on FDA approval and successful commercialization. This timeline, reflecting economic cycles, is irrelevant for CHEK compared to clinical and regulatory milestones.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Check Cap Ltd.
Check-Cap is developing an innovative capsule for colorectal cancer screening, a less invasive alternative to colonoscopy. The company's future revenue is entirely dependent on regulatory approval and adoption of this technology. This graph reflects analyst expectations for the commercialization of this unique diagnostic device.
%20profit%20of%20the%20company%20Check%20Cap%20Ltd.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Check-Cap-Ltd.&v=1772554272771 "Graph of future (projected) profit of the company Check Cap Ltd.")
Future (predicted) profit of companies in the market segment - Cancer analysis
Check-Cap is developing an innovative, swallowable capsule for colorectal cancer screening. It is a less invasive alternative to traditional colonoscopy. This graph shows forecasts for the oncology diagnostics sector, illustrating the enormous potential of technologies that can make early cancer detection more accessible and convenient for patients.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20analysis&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-analysis&v=1772554272799 "Graph of future (predicted) profits of companies in a market segment - Cancer analysis")
Future (predicted) profit of the market as a whole
For Check-Cap, a company developing innovative cancer diagnostic systems, this schedule is important for healthcare system budgets. Economic growth allows medical institutions to invest in new, expensive equipment. During recessions, cost savings are a priority.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772554272883 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Check Cap Ltd.
Check-Cap is developing an innovative capsule for colorectal cancer screening. Without a commercial product, its valuation, as shown in this chart, is based entirely on hope. Investors are evaluating the potential of its technology to transform medical diagnostics.
P/S market segment - Cancer analysis
Check-Cap is developing an innovative, swallowable capsule for colorectal cancer screening, offering a less invasive alternative to colonoscopy. This chart shows the average valuation in the oncology diagnostics sector, reflecting investor expectations for this technology, which could revolutionize cancer screening.
P/S of the market as a whole
Check-Cap Ltd. is developing an innovative, swallowable capsule for colorectal cancer screening. It is a less invasive alternative to colonoscopy. Future revenue depends on approvals and commercialization. This chart helps estimate the premium investors are placing on this potentially revolutionary product in medical diagnostics.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Check Cap Ltd.
Check-Cap is developing an innovative, swallowable capsule for colorectal cancer screening. The company's future revenue is entirely dependent on regulatory approval and commercialization of this product. The chart reflects investors' belief that this technology has the potential to transform the cancer diagnostics market.
%20P%2FS%20Check%20Cap%20Ltd.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Check-Cap-Ltd.&v=1772554272941 "The graph of the company's future (projected) P/S Check Cap Ltd.")
Future (projected) P/S of the market segment - Cancer analysis
Check-Cap is developing an innovative, swallowable capsule for colorectal cancer screening. This technology aims to be a less invasive alternative to colonoscopy. This chart shows how investors assess the commercial potential of this unique diagnostic device compared to other companies in the cancer testing field.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20analysis&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-analysis&v=1772554272948 "Future (projected) P/S market segment graph - Cancer analysis")
Future (projected) P/S of the market as a whole
This chart illustrates investor sentiment in the medical diagnostics field. For Check-Cap, the developer of an innovative colon cancer screening capsule, this is an indicator of the adoption of new technologies. Market optimism is essential to fund the implementation of less invasive and more patient-friendly diagnostic methods.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772554272998 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Check Cap Ltd.
Check-Cap is developing an innovative swallowable capsule for colorectal cancer screening, offering a less invasive alternative to colonoscopy. This graph will reflect revenue from sales of the C-Scan system following its approval and commercialization. Increased sales will signal the adoption of this new technology for mass cancer screening.
Sales of companies in the market segment - Cancer analysis
Check-Cap is developing an innovative, swallowable capsule for colorectal cancer screening. This graph illustrates the growth of the oncology diagnostics market. Check-Cap's technology offers a non-invasive alternative to colonoscopy, potentially significantly increasing screening coverage and facilitating early cancer detection, transforming the entire industry.
Overall market sales
Check-Cap Ltd. is developing an innovative capsule for colorectal cancer screening. Demand for its product after approval will depend on its inclusion in health insurance systems. The overall economic situation, shown in this graph, influences healthcare budgets and the willingness to pay for new, less invasive diagnostic methods.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Check Cap Ltd.
Check-Cap is developing an innovative, ingestible capsule for colorectal cancer screening, offering a less invasive alternative to colonoscopy. The company's future revenue is dependent on the approval and market acceptance of this technology. This chart reflects analyst expectations for the commercial potential of this new diagnostic method.
%20sales%20of%20the%20company%20Check%20Cap%20Ltd.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Check-Cap-Ltd.&v=1772554273167 "Schedule of future (projected) sales of the company Check Cap Ltd.")
Future (projected) sales of companies in the market segment - Cancer analysis
Check-Cap is developing an innovative, ingestible capsule for colorectal cancer screening. This graph illustrates the expectations for the cancer screening sector. It reflects the enormous need for less invasive and more convenient early detection methods, a key goal of Check-Cap's technology.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20analysis&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-analysis&v=1772554273197 "Schedule of future (projected) sales of companies in the market segment - Cancer analysis")
Future (projected) sales of the market as a whole
Check-Cap Ltd. is developing an innovative capsule for colorectal cancer screening that requires no bowel preparation. The company's commercial success depends on regulatory approval and adoption of the technology. This timeline, reflecting the overall economic situation, influences the willingness of healthcare systems to invest in new, more patient-friendly diagnostic methods.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772554273211 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Check Cap Ltd.
Check-Cap is developing a unique, swallowable capsule for colon cancer screening. The chart shows the financial status at the regulatory approval stage. Profitability is currently negative, as the company incurs significant costs for clinical trials and the US approval process. Success will open a huge market.
Market segment marginality - Cancer analysis
Check-Cap is developing an innovative, non-invasive capsule for colorectal cancer screening. For a company in the medical diagnostics industry, profitability depends on the accuracy of the technology and its market acceptance. This chart shows the average profitability in the sector, helping to assess the commercial potential of Check-Cap's product.
Market marginality as a whole
Check-Cap is developing an innovative, swallowable capsule for colorectal cancer screening. This overall market profitability curve is irrelevant to the company. The company's success depends on regulatory approvals and the acceptance of its less invasive technology by patients and physicians. Its market is driven by medical need.
Employees in the company, segment and market as a whole
Number of employees in the company Check Cap Ltd.
Check-Cap is developing an innovative colorectal cancer screening system based on a swallowable capsule. This graph shows the small team of engineers and clinicians working to obtain approval for this technology. Their number reflects the long and complex road to bringing a medical device to market.
Share of the company's employees Check Cap Ltd. within the market segment - Cancer analysis
Check-Cap is developing an innovative capsule for colorectal cancer screening without the need for invasive colonoscopy. This chart shows the percentage of biomedical engineers and clinicians the company is attracting in this niche diagnostic field. It reflects the concentration of talent needed to bring this breakthrough screening technology to market.
Number of employees in the market segment - Cancer analysis
Check-Cap is developing an innovative capsule for colorectal cancer screening that can be easily swallowed. This could make diagnosis much more comfortable. This graph shows how medtech companies are working to create less invasive diagnostic methods, which requires the involvement of engineers, programmers, and doctors to develop and implement such systems.
Number of employees in the market as a whole
Check-Cap Ltd. develops innovative systems for medical diagnostics. Advances in this field reduce costs for the entire healthcare system and improve quality of life. This employment graph reflects the economy, where the medical technology sector is a key growth driver, creating demand for engineers and IT specialists.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Check Cap Ltd. (CHEK)
Check-Cap is developing an innovative capsule (C-Scan) for colon cancer screening. This chart represents pure intellectual capital. The company has no mass sales; its value lies in this unique, patented technology. The chart shows how highly the market values this potentially breakthrough diagnostic product per engineer or scientist.
%20of%20the%20company%20Check%20Cap%20Ltd.%20(CHEK)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Check-Cap-Ltd.-CHEK&v=1772554273423 "Chart of market capitalization per employee (in thousands of dollars) of the company Check Cap Ltd. (CHEK)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer analysis
Check-Cap is developing an innovative capsule for colon cancer screening. In the medical technology sector, a company's value is determined by its unique product. The chart shows how much investors are betting on the team to bring this product to market. This is an assessment of the potential of their technology compared to other diagnostic companies.
%20by%20market%20segment%20-%20Cancer%20analysis&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-analysis&v=1772554273454 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer analysis")
Market capitalization per employee (in thousands of dollars) for the overall market
Check-Cap Ltd. is developing a non-invasive capsule for colorectal cancer screening. This graph shows the market-wide per-employee performance score, demonstrating how the market perceives the potential of this breakthrough diagnostic technology.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772554273487 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Check Cap Ltd. (CHEK)
Check-Cap is developing an innovative capsule for colorectal cancer screening (an alternative to colonoscopy). It's an R&D company in the commercialization stage. This graph likely represents the company's per-employee loss. It reflects how much the company spends on each engineer and salesperson to bring this complex product to market.
%20Chart%20Check%20Cap%20Ltd.%20(CHEK)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Check-Cap-Ltd.-CHEK&v=1772554273494 "Company Profit Per Employee (in thousands of dollars) Chart Check Cap Ltd. (CHEK)")
Profit per employee (in thousands of dollars) in the market segment - Cancer analysis
Check-Cap is developing an innovative capsule for colorectal cancer screening without the need for a colonoscopy. This medical startup's value lies in its unique technology. The data in this chart will likely reflect negative earnings per employee, as the company is in the development and clinical trials phase, incurring significant costs for its team of engineers and scientists.
%20in%20the%20market%20segment%20-%20Cancer%20analysis&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-analysis&v=1772554273512 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer analysis")
Profit per employee (in thousands of dollars) for the market as a whole
Check-Cap (CHEK) — (Note: CHEK has been delisted). This was an Israeli MedTech company developing a swallowable capsule (C-Scan) for colorectal cancer screening. It was an R&D business. This chart shows the average profitability per employee. It exemplifies how different the MedTech R&D model (where a single engineer can create IP worth billions) is from the average business.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772554273541 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Check Cap Ltd. (CHEK)
Check-Cap is developing an innovative capsule for colon cancer screening. This graph illustrates the long journey from idea to market in the medical device industry. The low current figures reflect the development and testing stage, but they hold enormous potential if approved and implemented.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Check-Cap-Ltd.-CHEK&v=1772554273553 "Sales chart per company employee Check Cap Ltd. (CHEK)")
Sales per employee in the market segment - Cancer analysis
Check-Cap was developing an innovative C-Scan capsule for no-prepare colon cancer screening. The company encountered challenges. This graph shows the average revenue per employee in the segment, reflecting the productivity benchmark for *successful* diagnostic companies that Check-Cap was aiming to achieve.
Sales per employee for the market as a whole
Check-Cap is an Israeli company that has developed an innovative capsule (C-Scan) for colorectal cancer screening. The company is currently in the approvals process. This metric is irrelevant, as they have no commercial revenue. The real value lies in their team's potential to bring this noninvasive test to market.
Short shares by company, segment and market as a whole
Shares shorted by company Check Cap Ltd. (CHEK)
Check-Cap is developing an innovative product—a capsule (C-Scan) that patients swallow for colon cancer screening, as an alternative to colonoscopy. This chart shows the bets that this technology won't take off. "Bears" believe the capsule won't be accurate enough or that the company won't gain FDA approval.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Check-Cap-Ltd.-CHEK&v=1772554273641 "Short Shares Chart for the Company Check Cap Ltd. (CHEK)")
Shares shorted by market segment - Cancer analysis
Check-Cap Ltd. is developing an innovative capsule (C-Scan) for colorectal cancer screening that patients swallow. It is a non-invasive alternative to colonoscopy. This chart shows the overall short position in the medical diagnostics sector. Its rise reflects investor doubts about the sector's ability to secure FDA approval for new, sophisticated diagnostic devices.
Shares shorted by the overall market
Check-Cap is developing an innovative capsule (C-Scan) for colon cancer screening. This chart illustrates the overall market pessimism. Investors see a company that has been struggling to bring a product to market for years. During times of fear, they lose patience and sell off shares, not believing in commercial success.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Check Cap Ltd. (CHEK)
This chart shows Check-Cap's long-standing struggles. The company is developing a swallowable capsule (C-Scan) for colon cancer screening as an alternative to colonoscopy. "Overheating" (above 70) occurs with any news of trial progress. Disappointing results, FDA delays, and a persistent cash crunch keep the stock "oversold" (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Check-Cap-Ltd.-CHEK&v=1772554273720 "RSI 14 indicator chart for the company's stock Check Cap Ltd. (CHEK)")
RSI 14 Market Segment - Cancer analysis
Check-Cap (CHEK) is a "capsule" instead of a colonoscopy (Israel). They (like Medtronic's PillCam) make a *swallowable capsule* (C-Scan) with *x-rays* for *screening* colon cancer. The "Cancer Analysis" sector (biotech/diagnostics) thrives on R&D. RSI_14_Seg shows the "temperature" of the *entire* industry. It helps understand: is CHEK's growth a niche or a general hype?
RSI 14 for the overall market
Check-Cap (CHEK), a cash-burning biotech, is its lifeline. This chart is its lifeline. During periods of market euphoria, investors are willing to "buy the dream" and fund unprofitable R&D projects. In moments of panic, the money supply is turned off, and investors demand profits, not promises, which puts CHEK at risk of survival.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast CHEK (Check Cap Ltd.)
Check-Cap is developing C-Scan, an innovative swallowable colon cancer screening capsule (an alternative to colonoscopy). This chart shows the analysts' average 12-month forecast, representing their collective bet on whether this technology will receive FDA approval and patient acceptance.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-CHEK-Check-Cap-Ltd.&v=1772554273845 "A chart showing analyst consensus forecasts for the expected stock price. CHEK (Check Cap Ltd.)")
The difference between the consensus estimate and the actual stock price CHEK (Check Cap Ltd.)
Check-Cap is an Israeli company that developed the C-Scan, a "pill-sized camera" for non-invasive colorectal cancer screening. It is a potential alternative to colonoscopy. This chart shows the upside and downside potential of the stock that analysts see. It measures the gap between the price and the forecast, reflecting their confidence in the technology.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-CHEK-Check-Cap-Ltd.&v=1772554273877 "A chart showing the difference between the consensus forecast and the actual stock price. CHEK (Check Cap Ltd.)")
Analyst consensus forecast for stock prices by market segment - Cancer analysis
Check-Cap is an Israeli MedTech company that developed the C-Scan, a swallowable capsule for colorectal cancer screening, an alternative to colonoscopy. This chart reflects analysts' general expectations across the cancer screening sector. It shows whether experts believe in a breakthrough in non-invasive diagnostic methods.
Analysts' consensus forecast for the overall market share price
Check-Cap is an Israeli medical device company developing C-Scan, a swallowable capsule camera for colon cancer screening (an alternative to colonoscopy). This chart shows the overall market "risk appetite." For Check-Cap, a company with a revolutionary but not yet approved technology, overall market optimism (risk appetite) is critical for funding.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Check Cap Ltd.
Check-Cap is a camera in a pill. It's an Israeli MedTech company that has been developing a swallowable capsule (C-Scan) for decades, which uses X-rays (not a camera) to scan the intestines for polyps (cancer). This graph is a summary of their battle with the FDA. It reflects their (very long and so far unsuccessful) path to FDA approval and their desperate fight to keep their money running.
AKIMA Market Segment Index - Cancer analysis
Check-Cap (CHEK) is an Israeli medical technology company that developed C-Scan, a swallowable colon cancer screening capsule that uses X-rays to create a 3D map of the colon without any preparation. The chart shows the average index for the segment, helping investors assess how this non-invasive technology compares to the market average.
The AKIM Index for the overall market
Check-Cap is a company developing a swallowable capsule for colon cancer screening. It is currently seeking strategic alternatives (mergers). This chart, reflecting the market average, is a backdrop. It helps assess how the underlying asset, whether technology or cash, compares to general macroeconomic fluctuations.
